From structural biology to designing therapy for inborn errors of metabolism by Wyatt W. Yue
SSIEM 2015
Wyatt W. Yue1
Received: 6 January 2016 /Revised: 9 February 2016 /Accepted: 11 February 2016 /Published online: 30 May 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract At the SSIEM Symposium in Istanbul 2010, I pre-
sented an overview of protein structural approaches in the
study of inborn errors of metabolism (Yue and Oppermann
2011). Five years on, the field is going strongwith new protein
structures, uncovered catalytic functions and novel chemical
matters for metabolic enzymes, setting the stage for the next
generation of drug discovery. This article aims to update on
recent advances and lessons learnt on inborn errors of metab-
olism via the protein-centric approach, citing examples of
work from my group, collaborators and co-workers that cover
diverse pathways of transsulfuration, cobalamin and glycogen
metabolism. Taking into consideration that many inborn errors
of metabolism result in the loss of enzyme function, this pre-
sentation aims to outline three key principles that guide the
design of small molecule therapy in this technically challeng-
ing field: (1) integrating structural, biochemical and cell-based
data to evaluate the wide spectrum of mutation-driven enzyme
defects in stability, catalysis and protein-protein interaction;
(2) studying multi-domain proteins and multi-protein com-
plexes as examples from nature, to learn how enzymes are
activated by small molecules; (3) surveying different regions
of the enzyme, away from its active site, that can be targeted
Introduction: Structure biology of metabolic
enzymes is advancing
The field of structural biology has come a long way since the
first protein crystal structure, that of sperm whale myoglobin,
in 1958. The Protein Data Bank, a public repository of struc-
tural data determined from x-ray crystallography, nuclear
magnetic resonance as well as electron microscopy (EM),
has recently reached its 100,000th entry in 2014. Protein struc-
ture determination has nowadays become a streamlined pro-
cess replete with technological advances that allow automa-
tion, parallelization and miniaturization of constituent steps
(Su et al 2015). Examples of such pioneering development
include heterologous expression systems to generate multi-
component protein complexes, automated chromatography
platforms for purification towards homogeneity, remedial
strategies for crystallization of protein samples, as well as
the implementation of high quality x-ray and electron diffrac-
tion sources worldwide.
In modern days, the term ‘structural biology’ is more ap-
propriately coined to cover the toolkit of biophysical and bio-
chemical, in addition to structural methods, that can probe the
oligomeric assembly (e.g. size exclusion, analytical ultracen-
trifugation), conformational changes (e.g. spectroscopy), en-
zyme catalysis (e.g. Michaelis-Menton kinetics), as well as
ligand/protein binding (e.g. isothermal titration calorimetry,
surface plasmon resonance) features of proteins. Structural
biology has therefore been instrumental in delineating the mo-
lecular functions and mechanisms of diverse target proteins,
including the hundreds of human metabolic enzymes associ-
ated with inborn errors of metabolism (IEMs) (Kang and
Stevens 2009; Yue and Oppermann 2011). Adopting a
family-wide and pathway-wide approach in target protein se-
lection (Osman and Edwards 2014), the Structural Genomics
Consortium has to date determined nearly 50 structures of
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for the design of allosteric activators and inhibitors.
human IEM-linked metabolic enzymes (Table 1), as a first
step towards developing a mechanistic understanding and
therapeutic advancement of these rare genetic diseases. Our
recent addition to this IEM repertoire includes structural de-
termination of six protein players (MUT, MMAA, MCEE,
MMACHC, MMADHC, MTR) involved in the different
stages of the processing, trafficking and assembly of the vita-
min B12 cofactor to its two destination enzymes (Froese et al
2010; Froese et al 2012; Froese et al 2015a, b). Inherited
defect in each gene of this intricate B12 processing pathway
gives rise to the metabolic disorders of methylmalonic
aciduria and homocystinuria (Froese and Gravel 2010).
As the field of structural biology gears towards the study of
larger, more complex, and more heterogeneous biological sys-
tems, the methods of x-ray crystallography and EM, tradition-
ally known for the respective strengths in the resolution and
size of samples, will likely evolve towards the middle ground
and dominate the playing field for next-generation protein
structure determination. On the one hand, x-ray crystallogra-
phy breaks new grounds on the size of macromolecular com-
plexes it can resolve, as evidenced in the recent 3.6 Å crystal
structure of yeast respiratory chain complex I, a mitochondrial
membrane-spanning machinery comprising >14 protein sub-
units (Zickermann et al 2015). On the other hand, an equally
impressive, 2.2 Å cryo-EM structure of an inhibitor-bound
human galactosidase (Bartesaghi et al 2015) demonstrated
the capability of EM to resolve ‘smaller’ complexes, but with
the necessary atomic resolution to reveal ligand binding
interactions.
An integrated (structural, biochemical,
computational) approach to characterize disease
causing mutations for IEMs
Inborn errors of metabolism are model subjects to be studied
by structural biology, due to two distinctive features. First, the
predominant majority of disease-causing mutations are within
the exonic region of the affected gene, rather than in the non-
coding introns. Hence they are expected to affect the integrity
(e.g. stability) and function (e.g. catalysis) of the encoded
enzyme (Yue et al 2014), a largely globular conformation well
suited for protein structure determination. Second, a large pro-
portion of these mutations (e.g. ~65 % of all genetic variants
for the metabolic disorders phenylketonuria, classical
homocystinuria and ornithine transcarbamylase deficiency)
are of the missense type that result in non-synonymous chang-
es of a single amino acid, as opposed to insertion or deletion of
larger peptide fragments.Missense changes are therefore more
‘subtle’ in character, context-dependent in function, and dic-
tated by the physico-chemical properties (e.g. size and hydro-
phobicity) of the mutated amino acid. Structures of the wild-
type and mutant metabolic enzymes determined at atomic
resolution (i.e. with the details to resolve individual amino
acid residues) prove useful in ascertaining the structural and
molecular principles for the amino acid substitution in the
local environment, as well as detecting mutation trends and
hotspot regions on the protein polypeptide as a whole (Froese
et al 2013; Shafqat et al 2013; Riemersma et al 2015).
Nevertheless, structural studies of disease-associated mu-
tant proteins are often more intractable than their wild-type
counterparts (Kang and Stevens 2009). This is because the
mutation defects that impact on the native integrity and func-
tion of the enzyme often precludes its recombinant production
in the quantity (milligrams) and quality (purity, homogeneity)
that are required for the in vitro biophysical, biochemical or
structural experiments. To complement this gap, a plethora of
in silico prediction methods have been developed (e.g. FoldX,
PolyPhen-2, SIFTand SNPs3d), adopting different algorithms
of sequence, physico-chemical and structural information, to
interpret the molecular effect and pathogenicity of amino acid
substitutions (For reviews, see Stefl et al 2013; Studer et al
2013 and references therein). For the modern-day high-
throughput pipeline in characterizing sequence variants, in
silico approaches are more preferable to experimental ap-
proaches, as the latter are time-consuming and require signif-
icant resource for the design and setup.
In silico methods also prove particularly useful in charac-
terizing those metabolic disorders with broad genotypes (i.e.
large numbers of disease-causing alleles), such as phenylke-
tonuria (MIM 261600), the most common inborn errors of
amino acid metabolism, where more than 400 out of 834 dis-
ease alleles annotated in the locus-specific database PAHvdb
(http://www.biopku.org/home/pah.asp) are due to missense
changes. A general lesson from surveying such a large
catalogue of mutations (Wettstein et al 2015) is that disease-
causing mutations, as opposed to the harmless variants, are
often accompanied by drastic changes in the physico-
chemical properties (polarity, hydrophobicity, charge, side-
chain geometry) and interaction networks (hydrogen bonds,
salt bridges, hydrophobic interactions) of the amino acid in-
volved. The mutated residues are also more commonly local-
ized within the protein core and conserved functional sites, as
reflected by their strong amino acid sequence conservation.
The utility of in silico prediction tools is also exemplified in its
application to triage a subset of all known disease mutations as
a starting point for experimental characterization of mutant
proteins. This is illustrated in the example of methylmalonyl
CoA mutase (MUT), one of the two destination enzymes re-
quiring the vitamin B12 cofactor for catalysis, where to date
>130 missense mutations are found on this 750-amino acid
polypeptide to cause methylmalonic aciduria (MIM 251000).
From a mapping of all known MUT mutations onto the pro-
tein crystal structure (Froese et al 2010), we selected 23 of
them representative of diverse exonic regions, clinical pheno-
types and ethnic populations, and performed a series of
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biochemical and cellular studies that characterize the protein
stability (recombinant expression level, differential scanning
fluorimetry) and enzyme catalysis (activity assay in patient
cells) (Forny et al 2014) (Fig. 1). Among the different molec-
ular defects catalogued from these mutations, we found that a
subset of mutants are thermally less stable than wild-type in
vitro, and can be partly rescued in vitro and in vivo by exog-
enous supplementation of chemical chaperones (CC) such as
glycerol, proline, betaine and trimethylamine N-oxide. These
CCs are low-molecular-weight osmolytes that stabilise pro-
teins, without directly interacting with them, by preferential
exclusion at the protein surface, thereby altering the thermo-
dynamic free energy of the protein in the solvent environment
(Arakawa et al 2006). Together, this study provides a proof of
concept that stabilizing mutant protein could be one therapeu-
tic strategy to rescue its defective function.
Small molecule drug development
for loss-of-function disorders is challenging
The availability of high-resolution protein structures has since
facilitated greatly the process of small molecule drug devel-
opment in human medicine (Yue et al 2014). Even before its
high-throughput advances, structural biology already played a
role in the lead optimization step of drug development, in
which structures of an established therapeutic target in com-
plex with a drug candidate can direct the chemical alterations
of the drug compounds to improve their affinity, potency and
selectivity. Nowadays, the timeframe of protein structure de-
termination has become sufficiently short, hence allowing its
application in other stages of the conventional drug discovery
pipeline. For example, protein structures can reveal
distinguishing features across different members of an
enzyme/domain family to explore specificity, detect binding
pockets and evaluate their ‘druggability’ (i.e. how amenable a
small molecule can bind to these pockets), guide compound
screening campaign using biophysical/in silico assays, and
develop structure-activity relationship for a chemical series
of compounds.
When considering therapeutic possibilities, inborn errors of
metabolism, like other genetic diseases, can be seen as a dys-
regulation of dosage for the associated protein (Beaulieu et al
2012). Depending on the particular disease, or even the dis-
ease allele, a genetic lesion can theoretically lead to a higher-
or lower-than-physiological level of the associated protein that
signify a gain-of-function (GOF) or loss-of-function (LOF)
phenotype, respectively. Our systematic study of PAH and
MUT mutations, as well as of other enzymes (McCorvie and
Timson 2013; Balmer et al 2014; Burda et al 2015), all con-
form to the general concept that IEMs are by and large LOF
diseases due to pathogenic mechanisms that effect the struc-
ture (e.g. misfolding, aggregation) and function (loss of catal-
ysis, loss of interactions) of the enzyme. This therefore poses a
conceptual challenge for drug discovery, since the most intu-
itive therapeutic target for an IEM (i.e. the metabolic enzyme
harbouring a LOF mutation itself) implies an imperative to
develop an activator of the deficient or defective enzyme
(Segalat 2007). While the drug development industry has
more traction in GOF diseases, by means of small molecule
inhibitors aimed at reducing the mRNA, protein or activity
levels, the road is much less travelled for developing a therapy
to activate or upregulate the levels of mRNA, protein or ac-
tivity as treatment for LOF diseases. With the explosion of
genomic data and disease linkage from the advent of next-
generation sequencing, novel therapy design and principles
are urgently required for LOF diseases (Boycott et al 2013).
Allosteric activators as next generation
pharmacological chaperones?
One emerging therapeutic approach for LOF diseases involves
the use of small molecule ligands known as pharmacological
chaperones (PCs) to stabilize and activate the mutant enzyme
(Muntau et al 2014), with the rationale that a moderate
Fig. 1 Cataloguing missense
mutations in methylmalonyl-CoA
mutase (MUT), applying a
combination of in silico,
biochemical and cellular methods
to characterize protein stability
and enzyme activity. Circles on
the MUT crystal structure
represent positions of missense
mutations in this study,
colour-coded to categorize their
identified molecular defects
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increase in the mutant enzyme activity beyond a certain
threshold level (e.g. 10 % of many lysosomal storage en-
zymes) could suffice to delay disease onset and ameliorate
phenotypes (Suzuki et al 2009). To date, PCs have promising
potentials for several IEMs, including the Fabry, Gaucher and
PompeDiseases, which have reached early-stage clinical trials
(Boyd et al 2013; Parenti et al 2015); while others are gaining
proof of concept (Santos-Sierra et al 2012; Jorge-Finnigan
et al 2013; Makley et al 2015). These first-generation PC
molecules often originate as substrate-mimetics or cofactor-
mimetics of the target enzymes, and the field of structural
biology has been useful in characterizing how the PC mole-
cule interacts with the enzyme active site (Bateman et al 2011;
Guce et al 2011; Torreblanca et al 2012; Suzuki et al 2014).
However, active-site-directed PCs create a conundrum in
which by binding to the active site, these ligands could poten-
tially compete with the native substrate or cofactor of the
target enzyme. Hence the counter-intuitive mode of action
for these PCs could restrict their application to certain sub-
inhibitory concentration and dosage window.
We propose that the next generation of PC molecules
should target an enzyme’s domains or pockets that are distant
from its active site, and therefore would not compete with the
enzyme’s native ligands. These allosteric, non-catalytic bind-
ing sites are often specific to an enzyme’s unique structure and
function, and necessitate structural and chemical biology ap-
proaches to help identification and validation. As a first lesson
to design allosteric PCs, my group has the vested interest in
understanding the molecular mechanism of naturally-
occurring enzymes built with a modality for ligand-binding
allosteric regulation. An example for such enzyme is
cystathionine-β-synthase (CBS) (Fig. 2a), which catalyzes
the conversion of homocysteine to cystathionine, a reaction
up-regulated by the native ligand of CBS, S-adenosyl-L-me-
thionine (SAM). Inherited mutations of the cbs gene lead to
classical homocystinuria (MIM 236200), in which protein
misfolding is the major cause of malfunction among the pre-
dominant alleles. In addition to a core catalytic domain
harbouring the enzyme active site, CBS contains a regulator
domain at its C-terminus which binds SAM in order to acti-
vate the catalytic domain (Pey et al 2013). We have applied
crystallography, biochemical and biophysical methods to ex-
plain how CBS is allosterically activated by SAM, by show-
ing that binding of SAM to the regulatory domain results in
large conformational change that relieves its steric inhibition
of the enzyme catalytic domain (McCorvie et al 2014). We
therefore posit that targeting the CBS regulatory domain with
a small molecule could be a strategy to activate mutant CBS
enzyme using the same native mechanism, thereby rescuing
disease alleles with defective enzyme activity.
CBS is not a lone example of allosteric activation via a
multi-domain protein architecture (Jaffe and Lawrence 2012;
Jaffe et al 2013). Similarly, the enzyme phenylalanine
hydroxylase (PAH), of which genetic mutations lead to
PKU, is activated by its own substrate phenylalanine (Phe),
postulated to bind not only to the enzyme active site in the
catalytic domain, but also to a separate regulatory domain
(Zhang et al 2014) (Fig. 2b). We recently provided the first
structural evidence that binding of Phe to the PAH regulatory
domain causes this domain to dimerize and, like CBS, relieves
its steric inhibition on the catalytic domain (Patel et al 2016).
We therefore believe that screening for small molecule binders
in allosteric sites such as the regulatory domains of CBS and
PAH could be a common principle for drug discovery of LOF
inborn errors of metabolism, at least in those enzymes with
allosteric sites. There are emerging studies identifying non-
inhibitory ligands in allosteric sites and cryptic pockets of
metabolic enzymes, either by means of high throughput
screening of large compound libraries (Marugan et al 2010;
Patnaik et al 2012; Porto et al 2012) or by the more chemistry-
efficient small molecule fragment approach (Landon et al
2009).
Multiple intervention avenues within a metabolic
pathway
When determining the appropriate therapeutic targets for a
metabolic disorder, it is often beneficial to look at the different
reaction steps around the affected enzyme of a metabolic path-
way, in order to maximize intervention possibilities (Fig. 3).
As an example, normal glycogen synthesis is catalysed by the
concerted action of three enzymes in humans: glycogenin
(GYG), glycogen synthase (GYS) and branching enzyme
(GBE). Andersen disease (MIM 232500) and adult
polyglucosan body disease (APBD; MIM 263570) caused
by GBE mutations, as well as Lafora disease due to mutations
in malin or laforin proteins (MIM 254780), are all neurolog-
ical diseases sharing a common neuropathology of malformed
glycogen (‘polyglucosan’) accumulation, although their ge-
netic defects affect different aspects of glycogen metabolism.
We have recently applied structural biology to characterize
GBE disease-causing mutations, in particular the prevalent
allele causing APBD, p.Y329S. A homology model of the
GBE mutant, based on the experimental wild-type crystal
structure (Froese et al 2015), shows that the Tyr329-to-Ser
substitution creates a cavity at the protein surface away from
the active site, and results in lower protein expression in vitro
and in vivo, and reduced protein stability. We reasoned that a
small molecule specifically targeting this surface-accessible
cavity could function as a ‘molecular strut’ to stabilize the
local defect of this mutant enzyme. As proof of therapeutic
principle, a tetra-peptide (Leu-Thr-Lys-Glu) designed compu-
tationally to fill this cavity can be taken up in patient cells,
binds specifically to mutant GBE protein and rescues mutant
enzyme activity to a moderate level (Fig. 3a).
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The peptide approach above can be considered an example
of pharmacological chaperone that is targeted directly at the
site of mutation defect, distant from the enzyme active site. An
alternative therapeutic avenue, however, can be based on sub-
strate inhibition, with the rationale that the same biosynthesis
enzymes for normal glycogen production are also responsible
for polyglucosan formation. Recently, a gene knockdown of
muscle glycogen synthase (GYS1) eliminated polyglucosan
formation and restored neurological functions in a mouse
model of Lafora disease (Pederson et al 2013), as well as a
neuronal model for APBD (Kakhlon et al 2013). These clin-
ical findings are further supported by the natural existence of
very rare GYS mutations which lead to its enzyme deficiency
(MIM 611556) with mild phenotypes in humans. Together,
they provide proof of principle that downregulation of glyco-
gen synthesis eliminates neurological abnormalities due to
polyglucosan formation, and lend support to the inhibition
of GYS1 enzyme activity, or its interaction with the functional
Fig. 2 Structural biology of two multi-domain metabolic enzymes with
regulatory modules. a Cystathionine β-synthase (CBS) is activated by S-
adenosyl-L-methionine (SAM) which binds to the C-terminal regulatory
domain (purple), and relieves its steric blockade of the catalytic domain
(blue). b Phenylalanine hydroxylase (PAH) is activated by its own sub-
strate phenylalanine (Phe) which binds to the N-terminal regulatory
domain (yellow) and relieves its steric blockade of the catalytic domain
(green). In both panels, a schematic domain organisation is shown on the
left, and a cartoon representation of the ligand-induced conformational
arrangement of regulatory domains is shown on the right. Structural data
that are available in support of this conformational mechanism are shown
in dash-lined boxes
Fig. 3 Different intervention strategies for a disease-linked enzyme
within a metabolic pathway. Defects in the disease-linked enzyme (E)
lead to the accumulation of substrate (S) and deficiency of product
metabolite (P), which are connected to the upstream (E−1) and
downstream (E+1) enzymes of the metabolic pathway. The different
points of intervention include a pharmacological chaperones, b
substrate reduction therapy and c functional bypass. An example of
pharmacological chaperone development is shown in Fig. 3a inset, for
the glycogen branching enzyme GBE1, where the prevalent disease
mutation p.Y329S (circled) creates a cavity at the protein surface. A
synthetic peptide LTKE (purple sticks) is designed to fill this void and
stabilize the mutant protein
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partner GYG necessary for glycogen synthesis, as potential
molecular therapy for Lafora and Andersen diseases, as well
as for the lysosomal storage disorder Pombe (GAAmutations)
whose hallmark is muscle glycogen accumulation. The inhi-
bition approach is particularly attractive to the drug develop-
ment industry, and can be considered as an example of ‘sub-
strate reduction therapy’ (Fig. 3b) where there is precedence in
IEMs (e.g. Miglustat for the treatment of Gaucher disease
(Platt and Jeyakumar 2008)) to reduce the consequence of
toxic metabolite accumulation due to defective enzymes
(Schiffmann 2015). We anticipate that progress in the struc-
tural biology of GYS and GYG (Chaikuad et al 2011; Zeqiraj
et al 2014) should pave the next step forward in developing
novel inhibitors for these enzymes. This example therefore
illustrates the principle of targeting different components of
a metabolic pathway for the treatment of a genetic disease. As
we enter the post-genomic era from the advent of next gener-
ation sequencing, with emerging new diseases (Ebrahimi-
Fakhari et al 2016) and unmet medical need, there is an urgent
call for novel, ‘imaginative’ routes of therapeutic intervention
to tackle IEMs, and rare diseases as a whole. To this end, a
recent example of functionally bypassing a deficient protein
by a suppressor mutation (Yoon et al 2014) may represent one
of many future therapeutic approaches aimed at activating an
alternative gene, isoform or enzymatic mechanism (Fig. 3c) to
functionally compensate for the defective gene and product.
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